Cardiovascular · AntihypertensiveRegulatory Approvalregulatorymid-term

FDA Grants AP Status for Irbesartan ANDA206194 by Hisun Pharm

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/18/2026, 12:32:31 AM

Assessment confidence: 67% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Hisun Pharm's ANDA for Irbesartan is significant as it introduces a new competitor in the antihypertensive market, potentially impacting pricing and market dynamics. Portfolio teams must evaluate the implications for existing products and strategize accordingly to maintain market share. Regulatory context from FDA (FDA AP — IRBESARTAN AND HYDROCHLOROTHIAZIDE (SUPPL)) supports the near-term read. Assessment grounded in 21 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing irbesartan products. The strongest clinical anchor is Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN (ClinicalTrials.gov), sponsor/company relevance (novartis). In Cardiovascular · Antihypertensive, 7 regulatory and 2 competitive items passed relevance filtering for Irbesartan.

Competitive Pressure

The most relevant competitive pressure comes from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals. This approval may enhance Hisun Pharm's position in the antihypertensive market, increasing competition against established brands.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — IRBESARTAN AND HYDROCHLOROTHIAZIDE (SUPPL) (FDA). Entity match (irbesartan); Regulatory pathway relevance (nda). The approval signifies a successful regulatory pathway for Hisun Pharm, which may encourage similar applications from other companies, impacting overall market compliance and dynamics.

Key Risks

Elevated medium regulatory exposure for Irbesartan could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community) could weigh on Irbesartan through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Hisun Pharm's entry could lead to increased competition, affecting pricing strategies and potentially reducing revenue for established brands in the antihypertensive segment.
Upside for Irbesartan may improve if Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing irbesartan products.

What Would Change This Assessment

This becomes more urgent if Monitor the launch timeline and market entry strategies of Hisun Pharm for Irbesartan.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — IRBESARTAN AND HYDROCHLOROTHIAZIDE (SUPPL)
FDAhigh relevance
Entity match (irbesartan); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SODIUM BICARBONATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MAGNESIUM SULFATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — ANDA219207
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DAPSONE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHYLERGONOVINE MALEATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — NINTEDANIB ESYLATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants W
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Physical Fitness, Cardiovascular and Brain Health
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals
Humanexa Signalsmedium relevance
Moderate corpus alignment

Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Optimizing estradiol serum levels for optimal skeletal and cardiovascular health during transdermal menopausal hormone therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Reduced antihypertensive treatment with maintained ambulatory blood pressure control following weight loss in type 2 diabetes.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Irbesartan

Commercial impact

medium

Hisun Pharm's entry could lead to increased competition, affecting pricing strategies and potentially reducing revenue for established brands in the antihypertensive segment.

Regulatory impact

medium

The approval signifies a successful regulatory pathway for Hisun Pharm, which may encourage similar applications from other companies, impacting overall market compliance and dynamics.

What to watch

Monitor the launch timeline and market entry strategies of Hisun Pharm for Irbesartan.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.